TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06617936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy:Tislelizumab With Recombinant human endostatin combined with Chemotherapy
Description: neoadjuvant therapy : Tislelizumab: 200mg, ivgtt, day 1 ; Recombinant Human Endostatin Injection (Endostar),210mg was pumped intravenously for 3 consecutive days; Pemetrexed (Non-squamous NSCLC) or Nab-paclitaxel(Squamous NSCLC):Pemetrexed: 500 mg/m\^2, ivgtt, day 1. Nab-paclitaxel: 260mg/m\^2, ivgtt, day 1.; Carboplatin:Carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 5 ivgtt on day 1 ; every 21 days for 1 cycle,2-4 cycles; (If the preoperative neoadjuvant did not reach 4 cycles, the treatment with ralizumab combined with recombinant human endostatin injection and chemotherapy for 1-2 cycles can be continued after surgery, and the total cycle of chemotherapy before and after surgery is up to 4 cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy:Tislelizumab With Recombinant human endostatin combined with Chemotherapy
Description: neoadjuvant therapy : Tislelizumab: 200mg, ivgtt, day 1 ; Recombinant Human Endostatin Injection (Endostar),210mg was pumped intravenously for 3 consecutive days; Pemetrexed (Non-squamous NSCLC) or Nab-paclitaxel(Squamous NSCLC):Pemetrexed: 500 mg/m\^2, ivgtt, day 1. Nab-paclitaxel: 260mg/m\^2, ivgtt, day 1.; Carboplatin:Carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 5 ivgtt on day 1 ; every 21 days for 1 cycle,2-4 cycles; (If the preoperative neoadjuvant did not reach 4 cycles, the treatment with ralizumab combined with recombinant human endostatin injection and chemotherapy for 1-2 cycles can be continued after surgery, and the total cycle of chemotherapy before and after surgery is up to 4 cycles)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: Patients who are discussed by the MDT panel to evaluate surgical resection will undergo surgery.Surgery must be done within the 4th-6th week from day 1 the last cycle of neoadjuvant treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy:Tislelizumab and Recombinant Human Endostatin Injection (Endostar)
Description: Adjuvant therapy Tislelizumab: 200mg, ivgtt, day 1 of each 21-day cycle, 17 cycles at most. Recombinant Human Endostatin Injection (Endostar):210mg was pumped intravenously for 3 consecutive days, every 21 days for 1 cycle,17 cycles at most.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Treatment
Description: Patients assessed by the MDT panel as inoperable for surgical treatment will be selected by the investigator for a standard treatment protocol determined by the MDT discussion
Study: NCT06619405

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Streetlab VR
Description: Streetlab VR is a virtual reality headset that is warn to simulate walking through a maze at different light levels.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Streetlab VR
Description: Streetlab VR is a virtual reality headset that is warn to simulate walking through a maze at different light levels.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Streetlab VR
Description: Streetlab VR is a virtual reality headset that is warn to simulate walking through a maze at different light levels.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Streetlab VR
Description: Streetlab VR is a virtual reality headset that is warn to simulate walking through a maze at different light levels.
Study: NCT06620874

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: STABHA Injection
Description: Participants will receive two ultrasound-guided STABHA injections into the medial collateral ligament of the knee at a 2-week interval

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-Concentration Glucose Water Injection
Description: Participants will receive two ultrasound-guided high-concentration glucose water injections into the medial collateral ligament of the knee at a 2-week interval

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline Injection
Description: Participants will receive two ultrasound-guided saline injections into the medial collateral ligament of the knee at a 2-week interval
Study: NCT06620419

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Perineal-applied electrical stimulation
Description: Small controller that outputs stimulation for stress incontinence and OAB, attached to a male-anatomy thin GelPad placed in the perineal area.
Study: NCT06622395

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Remote diagnosys
Description: Remote Diagnostic Arm (Teleconsultation): First Teleconsultation (V1): A child psychiatrist or psychologist specializing in ASD conducts the ADI-R (short version) interview with the parents or legal guardian via teleconsultation. The professional will score the items from the algorithm. After the consultation, the professional completes a questionnaire assessing the technical aspects of the remote interview (e.g., video quality, connection stability). Second Teleconsultation (V2): During the BOSA remote assessment, the professional sends the parent/caregiver instructions and a video link. The parent watches the video and follows guidance on how to position themselves and the child for optimal visibility. The parent then carries out the BOSA activities under supervision. The professional observes the child's behavior and provides time guidance. Two questionnaires are completed: one on the technical aspects of the consultation and the second on parent-child interaction.
Study: NCT06622811

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Students' Knowledge about Virtual Reality Questionnaire
Description: Part I: Personal Characteristics of Nursing Students:~It covers; age and gender.~Part II: Students' Knowledge about Virtual Reality Questionnaire:~This part will used to assess students' knowledge related to virtual reality that includes a definition of virtual reality, history of virtual reality, advantages and disadvantages of virtual reality on nursing education and equipment used for virtual reality and the effect virtual reality on future of education~Scoring system:~Respondents' answers will be scored (0) for incorrect answers, and (1) for correct answers. The overall items scores will be summed up and categorized according to the total percentages of unsatisfactory (\<60%) and satisfactory (≥60%).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: California Critical Thinking Disposition Inventory (CCTDI)
Description: It will consist of 24 items classify into 7 dimensions grouped as follows; truth-seeking (3 items); open-mindedness (4 items); analyticity (3 items); systematicity (4 items); critical thinking self-confidence (4 items); inquisitiveness (3 items); and cognitive maturity (3 items).~Scoring system:~Students asked to respond to all items with six points Likert scale as follows; strongly disagree = 1, disagree= 2, neutral = 3, sometimes agree = 4, agree = 5, and strongly agree= 6. The overall items scores will be summed up and categorized according to the total percentages of satisfactory critical thinking (≥75%) and unsatisfactory critical thinking (\<75%).
Study: NCT06620081

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Performance Tests
Description: Three functional tests were performed: the six-minute walk test, incremental lower limb test with arterial blood gas analysis, and lower limb endurance test with inspiratory capacity measurement. Each test was conducted on different days with different devices: HFNC and conventional oxygen therapy, totaling six test days. The inspired oxygen fraction (FiO2) was titrated to maintain normoxia between 90% to 96% and was kept constant for both interfaces.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Performance Tests
Description: Three functional tests were performed: the six-minute walk test, incremental lower limb test with arterial blood gas analysis, and lower limb endurance test with inspiratory capacity measurement. Each test was conducted on different days with different devices: HFNC and conventional oxygen therapy, totaling six test days. The inspired oxygen fraction (FiO2) was titrated to maintain normoxia between 90% to 96% and was kept constant for both interfaces.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Functional Tests
Description: Three functional tests were performed: the six-minute walk test, incremental lower limb test with arterial blood gas analysis, and lower limb endurance test with inspiratory capacity measurement. Each test was conducted on different days with different devices: HFNC and conventional oxygen therapy, totaling six test days. The inspired oxygen fraction (FiO2) was titrated to maintain normoxia between 90% to 96% and was kept constant for both interfaces.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Tests
Description: Three functional tests were performed: the six-minute walk test, incremental lower limb test with arterial blood gas analysis, and lower limb endurance test with inspiratory capacity measurement. Each test was conducted on different days with different devices: HFNC and conventional oxygen therapy, totaling six test days. The inspired oxygen fraction (FiO2) was titrated to maintain normoxia between 90% to 96% and was kept constant for both interfaces.
Study: NCT06621082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: After surgical resection，based on the patient's body surface area (BSA), the patient was given an oral dose of Simetinib bisulfate capsule (20-50mg bid) daily for 30 days for 6 cycles
Study: NCT06620094

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diabetes education videos
Description: In the initial meeting during the preparation phase, participants in the experimental group were informed about the notifications and diabetes education videos that would be sent to their phones. Afterward, the patients received three notifications daily, every day of the week. The first notification requested them to ;measure and record their fasting and postprandial blood sugar in the morning; The second notification instructed them to ;exercise for at least 30 minutes a day.; The third notification asked them to ;record the foods they consumed and their quantities, and to measure and record their evening fasting and postprandial blood sugar, as well as their blood sugar before going to bed.; Additionally, during their routine outpatient follow-ups, the results of their tests (A1C, BMI, total cholesterol, HDL, LDL, triglycerides), blood pressure, and weight measurements were recorded. Furthermore, three times a week, participants were asked to ;measure and record their blood pressur
Study: NCT06623318

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote therapeutic monitoring device
Description: IV Ensure proprietary remote therapeutic monitoring device is used to record and transmit data associated with date, time, and duration of IV medications administered in the home setting post-acute.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote therapeutic monitoring device
Description: IV Ensure proprietary remote therapeutic monitoring device is used to record and transmit data associated with date, time, and duration of IV medications administered in the home setting post-acute.
Study: NCT06622187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin (DDAVP)
Description: Patients in the intervention group will receive desmopressin 0.3ug/kg administered as an intravenous infusion 1h before the proposed procedure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride
Description: Patients in the control group will receive sodium chloride 0.9% 100mL administered as an intravenous infusion 1h before the proposed procedure
Study: NCT06623045

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training intervention
Description: The training program consisted of 12 weeks of PFM exercises, 3 times per week, with each session lasting between 10 and 15 minutes. The program followed different stages through the weeks: (1) proprioception of pelvic floor muscles activation and integration with diaphragmatic breathing, (2) stabilization and strengthening of the pelvic floor musculature through progressive overloading, and (3) transference of these exercises to FFT practice. During the 12 weeks, short contractions (2) were combined with longer ones (5 to 10), carrying out the progressive overload by increasing the number of contractions, the duration of the contraction, or by evolving the execution position towards more upright postures and sporting movements.
Study: NCT06623188

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auricular neuromodulation
Description: 3 neuromodulation sessions over 12 weeks

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham auricular neuromodulation
Description: 3 neuromodulation sessions over 12 weeks
Study: NCT06622551

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Iron-folic acid supplement
Description: The major thing distinguishing this clinical study from another clinical trial is that we differentiate intervention based on nutritional status as we want to observe whether different nutritional status, especially overweight/obese will diminish the effect of IFA supplementation.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron-folic acid supplement
Description: The major thing distinguishing this clinical study from another clinical trial is that we differentiate intervention based on nutritional status as we want to observe whether different nutritional status, especially overweight/obese will diminish the effect of IFA supplementation.
Study: NCT06621069

Intervention type: DRUG
Intervention: Bisphosphonates
Description: Alendronate Sodium or Zoledronic acid

Intervention type: OTHER
Intervention: Control
Description: control without BP
Study: NCT06731582

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide Tablet
Description: 1.5 grams/day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nicotinamide Placebo
Description: 2 tablets
Study: NCT05740969

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5Fluorouracil
Description: Cream

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imiquimod
Description: Cream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Cream
Study: NCT05335239

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Professional dental cleaning
Description: The dental nurse will visit at home and delivers professional dental cleaning, a reminder to use the fluoridated toothpaste (\> 4000 ppm ) and oral hygiene instruction to participants accompanied by home care aides, with manual toothbrush, fluoridated toothpaste (\> 4000 ppm) and relevant interproximal aids.
Study: NCT04949789

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo without Exercise
Description: 2 Capsules to be taken 30 minutes before breakfast.

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo with Exercise
Description: 2 Capsules to be taken 30 minutes before breakfast.

Intervention type: OTHER
Group type: OTHER
Intervention: IP I
Description: 2 Capsules to be taken 30 minutes before breakfast.

Intervention type: OTHER
Group type: OTHER
Intervention: IP II
Description: 2 Capsules to be taken 30 minutes before breakfast.

Intervention type: OTHER
Group type: OTHER
Intervention: IP III
Description: 2 Capsules to be taken 30 minutes before breakfast.
Study: NCT04985734

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Specific diagnostic work-up for ATTR-CM patients
Description: Technetium-scintigraphy
Study: NCT05955521

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: exosome and ctDNA evaluation
Description: Serial exosome and ctDNA evaluation during follow up period between neoadjuvant chemotherapy and surveillance after curative surgery.
Study: NCT05242575

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The information provided in the iVFT and control book parallel one another.
Description: An immersive virtual fled trip (iVFT) is a form of virtual reality (VR). The term immersive refers to an experience where the senses become heightened through multisensory input (e.g., visual, auditory, proprioceptive). When adding peripherals such as a head-mounted device (HMD) (e.g., goggles with 3D-lenses), a mobile phone becomes a pseudo-theater providing a 360-degree view that mimics the real world. For example, one can experience a simulated rollercoaster or visit the moon that may otherwise be inaccessible in day-to-day life. Also, a VFT provides for context and aids in background knowledge that is a crucial aspect of learning.~Participants will receive three interventions sessions each last 15-minutes.
Study: NCT05186038

Intervention type: DIAGNOSTIC_TEST
Intervention: iVYCHECK GIP Urine
Description: To determine the presence of Gluten Immunogenic Peptides (GIP) in urine samples using the immunochromatographic test iVYCHECK GIP Urine (Biomedal S.L).

Intervention type: DIAGNOSTIC_TEST
Intervention: CeliacDetect
Description: To determine the presence of IgA anti-tTG antibodies in blood samples using the immunochromatographic test CeliacDetect (Biomedal S.L).
Study: NCT05832918

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise therapy
Description: Exercise therapy is one of the rehabilitation methods that is defined as a regimen or plan of physical activities designed and prescribed to facilitate the patient's recovery from diseases and any conditions which disturb their movement and activity of daily life or maintain a state of well-being through neuro re-education, gait training, and therapeutic exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise therapy
Description: Exercise therapy is one of the rehabilitation methods that is defined as a regimen or plan of physical activities designed and prescribed to facilitate the patient's recovery from diseases and any conditions which disturb their movement and activity of daily life or maintain a state of well-being through neuro re-education, gait training, and therapeutic exercises.
Study: NCT04683939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT141
Description: Intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT141
Description: Intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT141
Description: Intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV
Study: NCT05214586

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Follow up of the clinical stage
Description: Pain, Swelling, Infection, Patient satisfaction and recurrence of the disease will be measured

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Follow up of the clinical stage
Description: Pain, Swelling, Infection, Patient satisfaction and recurrence of the disease will be measured
Study: NCT04819503

Intervention type: DRUG
Group type: OTHER
Intervention: Spinal anaesthesia (sub-study 1)
Description: We will conduct two sub-studies on the same patient group. Sub-study 1 is an observational study where patients with phantom and/or residual limb pain after lower limb amputation will be given spinal anaesthesia with 1% Chloroprocaine in an open label manner to investigate whether the peripheral nervous system is a necessary driver of their pain.

Intervention type: DRUG
Group type: OTHER
Intervention: Spinal anaesthesia (sub-study 1)
Description: We will conduct two sub-studies on the same patient group. Sub-study 1 is an observational study where patients with phantom and/or residual limb pain after lower limb amputation will be given spinal anaesthesia with 1% Chloroprocaine in an open label manner to investigate whether the peripheral nervous system is a necessary driver of their pain.

Intervention type: DEVICE
Group type: OTHER
Intervention: Repetitive transcranial magnetic stimulation (sub-study 2)
Description: After sub-study 1, the same patients will enter sub-study 2 where they are randomly assigned to receive either first active rTMS (10 days over 2 weeks), and then after a 9 week washout period, sham rTMS (10 days over 2 weeks), or they first receive sham rTMS, and then after 9 weeks of washout, active rTMS. Thus, patients undergo stimulation with deep rTMS in a double blinded randomised controlled trial with a 2 x 2 cross-over design, receiving both active and placebo stimulation

Intervention type: DEVICE
Group type: OTHER
Intervention: Repetitive transcranial magnetic stimulation (sub-study 2)
Description: After sub-study 1, the same patients will enter sub-study 2 where they are randomly assigned to receive either first active rTMS (10 days over 2 weeks), and then after a 9 week washout period, sham rTMS (10 days over 2 weeks), or they first receive sham rTMS, and then after 9 weeks of washout, active rTMS. Thus, patients undergo stimulation with deep rTMS in a double blinded randomised controlled trial with a 2 x 2 cross-over design, receiving both active and placebo stimulation
Study: NCT05328375

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth-enhanced Hybrid CR
Description: Participants in this group attend a total of 24 CR sessions (5 clinic-based + 19 home-based) over a 12-week period. Clinic-based sessions occur during the first week of the program and at the end of each month. Home-based sessions take place remotely once or twice per week via telehealth, depending on the week of the program. Patients are provided with onboarding sessions, remote patient monitoring devices (tablet, pulse oximeter, blood pressure monitor and cuff) and home-based exercise equipment (e.g., stationary bike and weights). Each CR session (clinic and home) is 60 minutes in duration and includes aerobic and resistance exercise training. Patients will also be asked to complete educational videos, as well as document their physical activity, dietary intake, medication management and homework sessions via surveys. Patients will be encouraged (but not required) to achieve ≥30 minutes of moderate aerobic activity, such as brisk walking, on ≥5 days per week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional CR
Description: Participants in this group attend a total of 24 clinic-based CR sessions according to standard of care protocols over a 12-week period. Each CR session is 60 minutes in duration and includes aerobic and resistance exercise training. In addition to scheduled sessions, patients will be asked to complete educational videos, as well as document their physical activity, dietary intake, medication management and homework sessions via surveys. Patients will be encouraged (but not required) to achieve ≥30 minutes of moderate aerobic activity, such as brisk walking, on ≥5 days per week.
Study: NCT06260046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: Induction: sufentanil TCI 0.3 ng/ml Maintenance: sufentanil TCI 0.05-0.5 ng/ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Induction: remifentanil TCI 3 ng/ml Maintenance: remifentanil TCI 0.5-5 ng/ml